Prescription Drug Risperdal
Risperdal is an “atypical” or “second generation” antipsychotic medication manufactured by Johnson & Johnson (“J&J”) that was initially approved by the FDA in 1993 to treat manifestations of psychotic disorders. In the early 2000s, the drug’s approval was more specifically designated for the treatment of symptoms associated with schizophrenia (with no pediatric indication). In October 2006, the FDA approved Risperdal for the treatment of irritability associated with autistic disorder in children and adolescents (between the ages of 5 and 16). Then, in 2007, Risperdal received approval for the treatment of schizophrenia in adolescents aged 13-17 years, and for the short-term treatment of acute manic or mixed episodes associated with Bipolar I disorder in children and adolescents ages 10-17 years.
Plaintiffs in the lawsuits are minor children and/or their guardians, as well as adults, that allege that as a result of ingesting and/or being injected with Risperdal, they developed serious side effects, including gynecomastia (abnormal breast development in males), rapid or long-lasting weight gain, galactorrhea and pituitary tumors.